key: cord-0859191-qh52bmqx
authors: Gupta, Maram Suresh; Kumar, Tegginamath Pramod
title: The potential of ODFs as carriers for drugs/vaccines against COVID-19
date: 2020-12-18
journal: Drug development and industrial pharmacy
DOI: 10.1080/03639045.2020.1862180
sha: 40943ae3df682fb0c9497da4507261771e3a5d01
doc_id: 859191
cord_uid: qh52bmqx

COVID-19 has spread out its wings across the globe and is taking away many lives. Millions of people are (self) quarantined to prevent the spread of this viral disease. World Health Organization (WHO) has affirmed that there is not any medicine for COVID-19. Besides, there is also no single drug that is approved by any regulatory agency for usage against this dangerous disease. Researchers across the globe are working tirelessly to fix an end to this virus and to save precious lives. While the research is in full swing, one is not sure whether they would come up with a chemical/herbal drug or a vaccine. Irrespective of the type of active ingredient for COVID-19, one needs to have a proper system to deliver the identified active ingredient to subjects/patients across the globe. Orodispersible films (ODFs) are excellent and attractive drug delivery carriers that have the potential to deliver drugs, herbal extracts, and vaccines. They are apt for patients who have a problem consuming traditional drug products such as tablets or capsules. The beauty of this dosage form is that it does not need water to consume by the subjects and can be readily administered to the tongue. The present review highlights the true potential of ODFs to act as a carrier for the delivery of various antiviral drugs/herbs/vaccines.

During the fag end of 2019, Wuhanthe most densely populated city and capital of Hubei Province -China was witnessing pneumonia whose etiology was unknown. At the beginning of 2020, the pathogen was successfully identified and was named as the 2019 novel corona virus (2019-nCoV) [1, 2] . Later, on 20 February 2020, the International Committee on Taxonomy of Viruses (ICTV) named it as Severe Acute Respiratory Syndrome Corona virus 2 (SARS-CoV-2), a new variant of SARS-CoV, and the disease caused was corona virus disease 2019 (COVID-19) [3] . Since then the whole world is on 'High Alert' due to this new viral threat. Millions of people have been (self) quarantined to prevent it from further spreading [4] . Nonetheless, the individuals infected by corona virus are augmenting everyday [5] . There are absolutely no drugs that are approved by regulatory agencies across the globe. In India, the Indian Council of Medical Research (ICMR) strongly recommended the usage of hydroxychloroquine for asymptomatic purposes [6] . Followed by this development, emergency use authorization was granted by United States Food and Drug Administration (USFDA) to promote the usage of chloroquine phosphate or hydroxychloroquine sulfate for treating COVID-19 [7] . World Health Organization (WHO) identified and recommended usage of remdesivir, lopinavir-ritonavir with or without interferon, immunotherapy, and recuperative sera. WHO also launched SOLIDARITY trials for the above-prescribed drugs to support that they are effective in treating COVID-19 [8] . In addition, novel chemical entities against the corona virus protease were also proposed by some researchers [9] and some have proposed various integrated Chinese and Western medicines for treating this pandemic [10] .

While the research is going on to identify an active agent for COVID-19. Identifying the mode of delivering the active moieties to patients and healthy subjects cannot be ignored. At present, there are several drug delivery systems, whereas the most novel and transformative drug delivery/carrier system is orodispersible films (ODFs). European Pharmacopoeia (Ph. Eur.) defines ODFs as 'single or multilayered sheets of suitable materials, to be placed in the mouth where they disperse rapidly' [11] . They are a type of oromucosal preparations which are ultra-thin, elegant, stamp sized, portable, patient friendly, and attractive dosage forms across all the age groups [12] . Clinical Data Interchange Standards Consortium (CDISC) defines ODFs as 'A thin layer or coating which is susceptible to being dissolved when in contact with a liquid' [13] . On the contrary, United States Pharmacopoeia (USP) employs a different terminology and called them as 'Oral Films' and defined as 'Thin sheets that are placed in the oral cavity. They contain one or more layers. A layer might or might not contain API' [14] . ODFs undergo rapid disintegration/dissolution and are usually swallowed along with saliva and a small amount of the drug gets absorbed via the oral mucosa due to its high vasculature [15, 16] .

ODFs are excellent and attractive carriers for delivery of various over the counter (OTC) or prescription drugs [17] , herbal extracts [18] [19] [20] [21] , vaccines [22] , probiotics [23] , and vitamins [24] . Drugs are either directly introduced [25] [26] [27] [28] in the formulation of ODFs or size reduced and converted to solid dispersions [29] or nanoparticles [30, 31] or solid lipid microparticles [32] or micronized and surface modified using silica [33] which not only help in enhancing the amount of drug that could be loaded on to ODFs but also help in enhancing the release rate and, bioavailability of the drug. At present, ODFs are used as an excellent carrier system for delivering various therapeutically active agents. The composition of ODFs includes a drug substance (natural or synthetic), a film-forming agent and plasticizer. Additionally, it also includes saliva stimulating agent, organoleptic agents, and stabilizers [12] . The critical quality characteristics of ODFs are its appearance, stability, water content, uniformity of the active agent, color, taste, aftertaste, and mouthfeel. Most importantly, it shall not cause irritation of mucosa when administered [34] . The authors provided an overview on characterization of ODFs to determine various quality parameters of ODFs and also introduced a 3D printed disintegration test apparatus for testing the disintegration time of ODFs using sensor technology [35] . ODFs are capable for drug delivery in patients with swallowing problems, mentally retarded patients, subjects with Parkinson's disease, bed-ridden patients, oral cancer patients, and uncooperative patients [36] [37] [38] . The present review is focused on critically analyzing the potential of ODFs as carriers for delivering antiviral drugs/herbs/vaccines with a potential for treatment of COVID-19, the global pandemic.

At present, there are no regulatory approved drugs for treatment of COVID-19. Current recommendations include supportive care, ventilator based assistance for respiration, usage of anti-infectives, antivirals, and glucocorticoid therapy [39] . National Health Commission of the People's Republic of China has provided some preferred drugs for treatment of COVID-19 that include interferon alpha, lopinavir/ritonavir, chloroquine phosphate, ribavirin, and arbidol. Some of the drugs that are presently at clinical trials stage are chloroquine, arbidol, remdesivir, and favipiravir [40, 41] . Of all these drugs lopinavir/ritonavir, chloroquine phosphate, and arbidol are administered via oral route. However, favipiravir appears to be the most potent and promising drug when compared to lopinavir/ritonavir. In India, Glenmark Pharmaceuticals has initiated phase III clinical trials for favipiravir and is expected to complete the trials by end of August 2020 [42] . The solubility of this drug is very poor in water and is necessary to convert it into its salt version (sodium or meglumine) and formulate it as an injection. A Chinese company by name Chengdu Xinhengchuang Pharmaceutical Co., Ltd. developed a tablet formulation that helps in overcoming the dissolution problem and achieved desired clinical results [43] . Table 1 The drugs that are being developed, mentioned in Table 1 , could face many challenges when it comes to delivering to the subject. For instance, favipiravir is associated with poor water solubility and demands an injection formulation. A potential alternative to such a disadvantage of favipiravir and other similar drugs is to formulate them as ODFs. Table 2 provides a list of antiviral drugs that were successfully formulated as ODFs. It is evident from Table 2 that drugs with low solubility, bioavailability, and dose are excellent candidates for formulating as films. The most conventional method used to prepare ODFs is solvent casting method and the modern methods include printing technologies using inkjet printing, wherein antiviral drugs are printed either alone or in combination with other drugs, for instance, anticancer drugs printed alongside antiviral drugs [64, 65] . In addition, antiviral ODFs can be prepared as a single layered or multi-layered dosage forms, example: entecavir [67] . Drugs could either be directly loaded onto ODFs or converted into nanoparticles before loading onto ODFs. The key ingredients include a film-forming material (polymer) and plasticizer. are not yet exposed and asymptomatic group can use Ayurvedic 'Swarna Prashana' and 'Rasayana' as potential immunity boosting agents [70] [71] [72] [73] . This in combination with social distancing helps in preventing the spread of disease [74] . Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homeopathy (AYUSH), Government of India recommends three immunity boosting measures. First and foremost is taking 10 g of Chyavanprash every day (not suitable to formulate as ODFs due to its heavy dose), second: drinking golden milk (milk with turmeric) twice a day, and lastly drinking herbal tea or a drink prepared by boiling tulsi, cinnamon, black pepper, dry ginger and raisin taken either by adding jiggery (natural sweet) or lemon juice for taste, if Chinese National Health Commission announced, dated 14 April 2020, three patented Chinese herbal drugs for treatment of COVID-19 which include namely: 'Lianhuaqingwen capsules and Jinhuaqinggan granules for mild conditions, and Xuebijing (injectable) for severe conditions' [80] . Luo et al. carried out an excellent review on Chinese herbal medicines that have the strong potential for usage in prevention of COVID-19. They have also reported the highly used herbs for preventing COVID-19 infections [81] . A Korean company by name, Biostandard Inc, reported usage of fermented Isatidis Radix Extract and claim to be effective against corona virus infections and they have protected the same by a Korean patent application [82] . Few other companies/academic institutions that have patent protected herbal extracts effective in preventing COVID-19 are provided in Table 3 . A decoction of various Ayurvedic herbs namely: 'Tinospora cordifolia, Zingiber officinale, Curcuma longa, Ocimum sanctum, Glycyrrhiza glabra, Adhatoda vasica, Andrographis paniculata, Swertia chirayita, Moringa oleifera, Triphala and Trikatu' have broad antiviral activity and protease inhibitor activity [88] [89] [90] . This decoction could be very useful in COVID-19 patients who are quarantined.

Turning now to ODFs of herbal extracts, Cure pharmaceuticals published US patent on herbs ((agrimony, andrographis paniculata, bistort, fenugreek, ginger, myrrh, solanum, etc.) tree and plant extracts ((licorice, shitake, sarsaparilla, slippery elm, etc.), and essential oils (clove, camphor, cinnamon, lemon, spearmint, etc.) that are formulated as multilayered edible oral thin films for management of cough/Pharyngitis [91] . Table 4 provides a list of ODFs formulated using herbal extracts. From the table, it is evident that solvent casting method is the most preferred method to fabricate herbal ODFs. Zim laboratories limited, a leading Indian company in the domain of oral thin films has published a research article on oral dissolving films of ginger [21] . Visser et al. reported ODFs of five Indonesian medicinal plants extracts namely: Lagerstroemia speciosa, Phyllanthus niruri, Cinnamomum burmannii, Zingiber officinale, and Phaleria macrocarpa [92] were prepared by solvent casting method [95] . Of these plant extracts, Phaleria macrocarpa and Zingiber officinale are associated with antiviral activity [96, 97] . Song et al. evaluated antiviral activity of quercetin-7-glucoside isolated from Lagerstroemia speciosa [98] . Sri Wahyuni et al. reported antiviral activity of Phyllanthus niruri, particularly they reported its activity against hepatitis C virus [99] . Verma et al. reported ODFs of Piper betel and Foeniculum officinalis [93] . Foeniculum officinalis is reported to possess antiviral and antioxidant activity [100] .

Similarly, Pawar and Butle reported ODFs of Allium sativum [94] , a potent antiviral agent [101] .

Generally speaking, ODFs are well known to act as carriers for various herbal extracts [18] [19] [20] [21] . But, from the above explanation, it is particularly evident that they have the potential to act as carriers to aid in the delivery of various antiviral herbs.

The Center for Disease Control and Prevention defines vaccines as 'A product that stimulates a person's immune system to produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually administered through needle injections, but can also be administered by mouth or sprayed into the nose' [102] . Vaccination is considered as one of the most effective ways of preventing cause of a disease [103] . At present, there are several companies, academic institutes that are actively working to develop a vaccine against COVID-19. Vaccines that are currently under development are provided in Table 5 .

Primarily, vaccines pose extreme challenges vis-a-vis its handling, (cold) storage and shipping, all expensive propositions. For instance, one of the studies reported that 38 billion USD would be spent on transportation and administration of 18 vaccines in 94 countries [123, 124] . Therefore, there is a need for alternate dosage forms that can help reducing the cost. For instance, Vaxart Inc is developing recombinant vaccine for COVID-19 in tablet formulation using its patent protected technology called VAAST [107] [108] [109] . RP Scherer Technologies LLC is also developing a tablet formulation (fast dissolving) for influenza vaccine with starch as immune stimulating agent [125] . Tablets are highly traditional and . Some of the vaccine preparations that are successfully formulated as ODFs are provided in Table 6 . Administration of vaccines using fast dissolving buccal films is the most optimized form of administration as it has plethora of advantages when compared with parenteral route of administration [132] . Research suggests that vaccines administered via oral route are as good as or even better than those that are administered via parenteral route. For instance, Bajrovic et al. demonstrated that oral administration (sublingual and buccal routes) of influenza virus vaccine as a thin film formulation has shown good or better results than the vaccine that is administered via intramuscular route [133] . From Table 6 , it is evident that ODFs comprising vaccines can be prepared as mono or bilayered using the most popular solvent casting method. Tian et al. prepared influenza virus vaccine by using trehalose and pullulan to maintain the stability and antigenicity of the vaccine. They also employed hypromellose that further helped in enhancing the stability of the film [134] . ODFs remain an excellent option for delivery of vaccines to subjects across all the age groups. They are easily portable and maintain stability of the vaccine during transportation till it reaches to the subject for consumption. All these strongly suggest that ODFs are cost-effective carriers and easy to consume dosage forms.

In light of the above, ODFs are a novel oromucosal carriers that could be used to deliver a new active agent (drug/vaccine) against COVID-19. ODFs have already proven its potential to act as a carrier for delivery of drug/herb/vaccine. But, more research is still needed vis-a-vis loading vaccines onto ODFs. Research in the domain of corona virus infections has taken the front seat across the globe and companies are heavily investing in R&D. Hopefully, soon the world will witness a new active entity for treating COVID-19 and the life of all the human beings will come to normalcyfrom unusual to life as usual.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

The different clinical characteristics of corona virus disease cases between children and their families in China -the character of children with COVID-19

Pneumonia of unknown cause -China', emergencies preparedness, response, disease outbreak news

The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Novel Wuhan (2019-nCoV) coronavirus

COVID-19) dashboard

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Coronavirus disease 2019 (COVID-19) and antirheumatic drugs

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease

Efficacy and safety of integrated traditional Chinese and western medicine for corona virus disease 2019 (COVID-19): a systematic review and meta-analysis

European Pharmacopoeia

Orodispersible thin films: a new patient centered innovation

Pharmaceutical dosage forms. United States Pharmacopoeia

Advances in orodispersible films for drug delivery

Design and evaluation of bilayered buccal film preparations for local administration of lidocaine hydrochloride

Oromucosal films: from patient centricity to production by printing techniques

Cannabinoid oral dispersible film strip

Oral thin films comprising plant extracts and methods of making and using same

Preparation and characterization of nanocomposite films based on gum arabic, maltodextrin and polyethylene glycol reinforced with turmeric nanofiber isolated from turmeric spent

Development of Zingiber officinale in oral dissolving films: effect of polymers on in vitro, in vivo parameters and clinical efficacy

Oral thin film vaccine preparation

Novel probiotic dissolvable carboxymethyl cellulose films as oral health biotherapeutics: in vitro preparation and characterization

Preparation and evaluation of orally disintegrating film containing donepezil for Alzheimer disease

Formulation of a novel tianeptine sodium orodispersible film

Micronized zaleplon delivery via orodispersible film and orodispersible tablets

Evaluation of self-nanoemulsifying drug delivery systems using multivariate methods to optimize permeability of captopril oral films

Orodispersible films containing ball milled aripiprazolepoloxamer V R 407 solid dispersions

Formulation and characterization of fast dissolving oral films containing buspirone hydrochloride nanoparticles using design of experiment

Development of fast dissolving oral films containing lercanidipine HCl nanoparticles in semicrystalline polymeric matrix for enhanced dissolution and ex vivo permeation

A new melatonin oral delivery platform based on orodispersible films containing solid lipid microparticles

Incorporation of surfacemodified dry micronized poorly water-soluble drug powders into polymer strip films

Oral films: current status and future perspectives

Characterization of orodispersible films: an overview of methods and introduction to a new disintegration test apparatus using LDR-LED sensors

New prospective in treatment of Parkinson's disease: studies on permeation of ropinirole through buccal mucosa

Personalized medicine in pediatrics: the clinical potential of orodispersible films

Oral thin films as a remedy for noncompliance in pediatric and geriatric patients

Office of the State Administration of Traditional Chinese Medicine. Notice on issuing a new coronary virus pneumonia diagnosis and treatment guidelines

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia. The 6th ed

Glenmark begins phase III trials of favipiravir for Covid-19 in India

Favipiravir pharmaceutical composition containing different particle size ranges

Anti-CD3 antibody formulations. Tiziana Life Sciences PLC

Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer. Tiziana Life Sciences PLC

Development and characterization of an orodispersible film containing drug nanoparticles

Formulation and optimization of a novel oral fast dissolving film containing drug nanoparticles by Box-Behnken design-response surface methodology

Mechanical characterization and ex vivo evaluation of anticancer and antiviral drug printed bioadhesive film for the treatment of cervical cancer

Behavior of printable formulations of loperamide and caffeine on different substrates-effect of print density in inkjet printing

Enhancement of solubility and optimization of orally disintegrating films of acyclovir

Orodispersible film formulation containing entecavir. Korea: Sunsystems Co. Ltd. International patent publication number WO2016052781

World Health Organization

COVID-19 pandemic: a pragmatic plan for Ayurveda intervention

Clinical effect of suvarna bindu prashan

Building bridges between Ayurveda and Modern Science

Antioxidant activity of brahma rasayana

Use of herbal drugs to treat COVID-19 should be with caution

Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs

Antiviral composition comprising of fermented Isatis indigotica root extract and its thereof. Korean patent application no

Prickly ash preparations and uses thereof as antiviral agents

Bicalin and its derivatives as a treatment for SARS corona virus infection or other related infections

Composition comprising extract of Angelica dahurica root or furanocoumarins isolated therefrom for preventing or treating avian influenza, swine influenza or corona virus

Herbal composition containing sea salt. US patent publication no

Herbal composition comprising ginger and goldenrod for the treatment of cold and flu. International patent publication no

Evaluation of Ocimum sanctum and Tinospora cordifolia as probable HIV-protease inhibitors

Evaluation of some medicinal plants as putative HIV protease inhibitors

Multi-target b-protease inhibitors from Andrographis paniculata: in silico and in vitro studies

Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films

Development of orodispersible films with selected Indonesian medicinal plant extracts

Development and evaluation of oral film of herbal extracts of Piper betel and Foeniculum officinalis

Development of formulation and evaluation of garlic orodispersible films

Quality by design approach for optimizing the formulation and physical properties of extemporaneously prepared orodispersible films

In vitro antiviral activity of aqueous extract of Phaleria macrocarpa fruit against herpes simplex virus type 1

Fresh ginger (Zingiber officinale) has anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines

Anti-viral activity of Phyllanthus niruri against hepatitis C virus

Evaluation of antiviral and antioxidant activity of selected herbal extracts

Garlic: a review of potential therapeutic effects

World Health Organization -vaccines

Recombinant polypeptides for membrane fusion and uses thereof

Formulations for small intestinal delivery of RSV and norovirus antigens. Vaxart, Inc. US patent publication no

Formulations for small intestinal delivery

Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form viruslike particles (VLPs) that protect mice against challenge with SARS-CoV

Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants

Compositions comprising Iscom particles and live microorganisms

Costs of vaccine programs across 94 low-and middle-income countries

Projections of costs, financing, and additional resource requirements for lowand lower middle-income country immunization programs over the decade

Oral vaccine fast dissolving dosage form using starch

Quick-dissolving oral thin film for targeted delivery of therapeutic agents. US patent application no

WT1 peptide cancer vaccine composition for mucosal administration

Methods and compositions for stabilization of a virus vaccine

Formulation for room temperature stabilization of a live attenuated bacterial vaccine

Overview and future potential of fast dissolving buccal films as drug delivery system for vaccines

Novel technology for storage and distribution of live vaccines and other biological medicines at ambient temperature

Development of an orodispersible film containing stabilized influenza vaccine